Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CG1801 and CGL1802 in Healthy Volunteers
NCT03774355Phase 1Completed
- Sponsor
- Crystal Genomics
- Start
- Dec 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of polmacoxib in osteoarthritis (OA) (2 arms), sponsored by Crystal Genomics. Primary endpoints: Area Under Curve [AUC]last at Day 1 and Maximum Plasma Concentration at Day 1. Started Dec 2018; status: completed.
02
Drugs
polmacoxib
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03774355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03774355.